The metabolic evaluation of pemafibrate in nonalcoholic fatty liver disease‐related cardiovascular diseases-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The metabolic evaluation of pemafibrate in nonalcoholic fatty liver disease‐related cardiovascular diseases

Published:2023-04-10 Issue:8 Volume:53 Page:786-787
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatology Research

Author:

Chung Hsien‐Hui¹²³^ORCID

Affiliation:

1. Department of Pharmacy & Clinical Trial Pharmacy Kaohsiung Veterans General Hospital Kaohsiung City Taiwan

2. Preventive Medicine Program Center for General Education Chung Yuan Christian University Taoyuan City Taiwan

3. Department of Pharmacy and Master Program College of Pharmacy and Health Care Tajen University Pingtung County Taiwan

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hepr.13903

Reference11 articles.

1. Safety and efficacy of switching to pemafibrate from bezafibrate in patients with chronic liver disease

2. Alkaline phosphatase: a novel treatment target for cardiovascular disease in CKD

3. Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease

4. Review article: vascular effects of PPARs in the context of NASH

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP